Recent developments in therapeutic cancer vaccines
Michael A Morse*, Stephen Chui, Amy Hobeika, H Kim Lyerly and Timothy Clay
Correspondence *Duke University Medical Center, MSRB Room 401, Research Drive, Box 3233, Durham, NC 27710, USA
Email michael.morse@duke.edu
While the potential for therapeutic cancer vaccines has been recognized, based on modest clinical trials in the metastatic setting, a gap exists between the limited clinical activity of cancer vaccines and promising preclinical findings. Morse et al. discuss the relevance of appropriate platforms for cancer vaccine testing, identification of the most important biologic endpoints, and reiterate the need to improve our understanding of how to manipulate the immune system beyond the initial vaccine-induced stimulation. The authors focus on the areas of cancer vaccine development that will translate into clinical application.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.